Executives On The Move: Boehringer Announces US Promotion, Immatics Chooses A CMO And DalCor Pharma Fills C-Suite Commercial Post
Boehringer Ingelheim announces its BI Pharma president to take helm from retiring US country managing director and chief executive officer. Immunotherapeutics developer Immatics Biotechnologies chooses GSK cell therapy head as CMO, and precision medicine firm DalCor Pharmaceuticals picks a chief commercial officer.
You may also be interested in...
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Executives On The Move: Clinical Positions Filled At Gilead, Sanifit and Spectrum, And Ferring Pharma US Officer Is Promoted
Anti-viral pharma Gilead Sciences, vascular calcification treatment firm Sanifit and hematology and oncology drug developer Spectrum Pharmaceuticals each select a new VP, clinical development. Also, to oversee its group in the US, multinational Ferring Pharmaceuticals promotes its US chief commercial officer to president.
Executives On The Move: Ipsen Decides On New Leader, A CSO for 4P-Pharma And A CFO During Transition for Histogen
Paris, France-based Ipsen decides on a Sanofi Pasteur exec for CEO and Roche Institute head joins cancer and inflammatory therapy company 4P-Pharma as CSO. Meanwhile, regenerative medicine firm Histogen brings on a new CFO during its transition to a public company.